How I treat monoclonal gammopathy of renal significance (MGRS)

Jean Paul Fermand, Frank Bridoux, Robert A. Kyle, Efstathios Kastritis, Brendan M. Weiss, Mark A. Cook, Mark T. Drayson, Angela Dispenzieri, Nelson Leung

Research output: Contribution to journalArticlepeer-review

171 Scopus citations


Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases.

Original languageEnglish (US)
Pages (from-to)3583-3590
Number of pages8
Issue number22
StatePublished - Nov 21 2013

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'How I treat monoclonal gammopathy of renal significance (MGRS)'. Together they form a unique fingerprint.

Cite this